是否寻求基因治疗?异基因造血细胞移植受者移植失败后可行吗
本文讨论既往接受异基因造血细胞移植(HCT)后移植物失败的患者,是否可考虑自体造血干细胞(HSC)基因治疗(GT)。文章围绕患者与HSC健康相关因素分析可行性及共同决策,指出慢性炎症应激和预处理化疗可能损害HSC适合度、降低造血储备、加速HSC衰老并促进有害基因突变积累,从而可能不利影响GT的安全性和疗效。
要点
- 既往异基因HCT后移植物失败者接受自体GT的安全性和疗效尚不明确。
- 慢性炎症应激和预处理化疗可能损害HSC适合度并降低造血储备。
- 上述暴露还可能加速HSC衰老并促进有害基因突变积累。
核心结论
- 既往异基因HCT后移植物失败的患者是否可考虑自体HSC基因治疗,其安全性和疗效尚不明确,需结合患者与HSC健康相关因素进行共同决策。
研究设计与样本
- 本文为综述性文章,讨论与患者和HSC健康相关的多种因素对自体GT可行性的可能影响及共同决策。
主要发现
- 慢性炎症应激和预处理化疗可能损害HSC适合度、降低造血储备、加速HSC衰老并促进有害基因突变积累。
- 上述因素均可能不利影响GT的安全性和疗效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two autologous hematopoietic stem cell (HSC)-based gene therapies (GTs) are now commercially available for severe sickle cell disease and transfusion-dependent β-thalassemia. However, the safety and efficacy of a subsequent autologous HSC-based GT after graft failure with a previous allogeneic hematopoietic cell transplant (HCT) remains unclear. Some individuals who have experienced a failed first attempt at a potentially curative therapy might seek a second opportunity for cure via GT. In this article, we discuss various factors related to patient and HSC health that may influence feasibility, and shared decision-making regarding whether an individual who has previously received an allogeneic HCT and experienced graft failure could consider an autologous GT. Exposure to chronic inflammatory stress and conditioning chemotherapy may compromise HSC fitness, reduce hematopoietic reserve, accelerate HSC aging, and promote the accumulation of deleterious genetic mutations, all of which may adversely affect the safety and efficacy of the GT.
引用
- Sharma A, John T. To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients. Blood Adv. 2025. PMID: 40472294. doi:10.1182/bloodadvances.2024015413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。